The investigation by Levi & Korsinsky into AstraZeneca for potential securities law violations, coupled with the Chinese fraud probe, is likely to negatively impact investor sentiment and the stock price in the short term. The involvement of senior executives and multiple Chinese government agencies adds to the seriousness of the situation.